# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Matthew Caufield reiterates HilleVax (NASDAQ:HLVX) with a Neutral and maintains $2 price tar...
HilleVax (NASDAQ:HLVX) reported quarterly losses of $(0.83) per share which missed the analyst consensus estimate of $(0.43) by...
The reduction of approximately 41 employees, or approximately 40% of the company's workforce, is intended to preserve cash ...
Leerink Partners analyst David Risinger downgrades HilleVax (NASDAQ:HLVX) from Outperform to Market Perform and lowers the p...
Stifel analyst Stephen Willey downgrades HilleVax (NASDAQ:HLVX) from Buy to Hold and lowers the price target from $34 to $3.
HC Wainwright & Co. analyst Matthew Caufield downgrades HilleVax (NASDAQ:HLVX) from Buy to Neutral.
U.S. stocks started the week on a neutral note, with the S&P 500 and Nasdaq 100 indices hovering around the flatline by mid...